GGrantIndex
Sort

64,565 grants matching drug discovery

The Dana-Farber Cancer Institute Cancer Target Discovery and Development Center

$968,937
William C Hahn · Dana-Farber Cancer Inst · U01 · FY2019 · CA

Connectivity Map 100k

$968,711
Todd R. Golub · Broad Institute, Inc. · RC2 · FY2010 · HG

Transporter Elucidation Center at the University of California, San Francisco

$968,661
Kathleen M Giacomini · University Of California, San Francisco · UC2 · FY2025 · HD

Characterization of the Pharmacokinetic/Pharmacodynamic (PK/PD) Profile of a Candidate HIV Prevention Drug in Rhesus Macaques

$968,613
Peter Silvera · Advanced Bioscience Laboratories, Inc. · N01 · FY2022 · AI

Robust Predictor of Colon Cancer Risk

$968,518
Harry Ostrer · Morgan And Mendel Genomics, Inc. · R42 · FY2022 · CA

POP: 2/22/17-2/21/21. PRECLINICAL MEDICATIONS DISCOVERY AND ABUSE LIABILITY TESTING FOR NIDA. N01DA-17-8932. PURPOSE: TO EXERCISE OPTION QUANTITY 1(CO

$968,474
Patrick Beardsley · Virginia Commonwealth University · N01 · FY2020 · DA

Disease Modifying Biologics for Rheumatoid Arthritis

$968,470
Rekha Bansal · Novelmed Therapeutics, Inc. · R44 · FY2012 · AG

A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with an attenuated, live sporozoite malaria vaccine

$968,360
Stephen Lev Hoffman · Sanaria, Inc. · R44 · FY2024 · AI

Immobilized Receptors In Drug Discovery

$968,328
Irving William Wainer · National Institute On Aging · ZIA · FY2012 · AG

OSU as a Network Lead Academic Participating Site for the NCI NCTN

$968,250
Claire F Verschraegen · Ohio State University · UG1 · FY2023 · CA

Cannabinoid CB1 and CB2 receptors and drug abuse

$968,160
Zheng-Xiong Xi · National Institute On Drug Abuse · ZIG · FY2022 · DA

A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with an attenuated, live sporozoite malaria vaccine

$968,151
Stephen Lev Hoffman · Sanaria, Inc. · R44 · FY2023 · AI

Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD

$967,956
William C Raschke · Virogenics, Inc. · R44 · FY2019 · AI

Informatics Tools for High-Throughput Sequences Data Analysis

$967,608
Eric Banks · Broad Institute, Inc. · U01 · FY2015 · HG

Rapid-Response Crystallography

$967,605
Marc Allaire · University Of Calif-Lawrenc Berkeley Lab · P30 · FY2023 · GM

Connectivity Map 100k

$967,265
Todd R. Golub · Broad Institute, Inc. · RC2 · FY2009 · HG

Development of a Commercial Platform for Discovery and Validation of Key Microbial Metabolites in CNS Disorders

$967,251
Todd Z Desantis · Second Genome, Inc. · R44 · FY2020 · DA

Biostatistics Resource

$967,148
Donald A Berry · University Of Tx Md Anderson Can Ctr · P30 · FY2009 · CA

Developmental Funds

$967,046
Stanton L Gerson · Case Western Reserve University · P30 · FY2019 · CA

Identifying and targeting collateral lethal vulnerabilities in cancers

$967,038
Ronald Anthony Depinho · University Of Tx Md Anderson Can Ctr · U01 · FY2023 · CA

Identifying and targeting collateral lethal vulnerabilities in cancers

$967,038
Ronald Anthony Depinho · University Of Tx Md Anderson Can Ctr · U01 · FY2025 · CA

Hybrid Molecules Designed to Enhance Antibiotic Activity

$967,036
George E Wright · Glsynthesis, Inc. · R44 · FY2008 · AI

Active Immunization for Treating Methamphetamine Abuse

$966,958
S. Michael Owens · Univ Of Arkansas For Med Scis · U01 · FY2010 · DA

Wisconsin and New Jersey Alliance in Precision Experimental Therapeutics

$966,949
Salma Jabbour · Rbhs -Cancer Institute Of New Jersey · UM1 · FY2019 · CA

A Web Service for Fragment-based Selectivity Analysis of Drug Leads

$966,453
John Laurence Kulp III · Conifer Point Pharmaceuticals, Llc · R44 · FY2023 · GM